Results 71 to 80 of about 477,278 (318)
Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source
Use of gemtuzumab ozogamycin combined with conventional chemotherapy in patients with acute myeloid leukemia [PDF]
Einstein (São Paulo), 2011 Objective: To analyze the outcome of patients treated withgemtuzumab ozogamycin combined with conventional therapy treatedat Hospital Israelita Albert Einstein.
Guilherme Fleury Perini +9 more
doaj
Molecular Oncology, EarlyView.In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim +11 more
wiley +1 more source
Molecular Oncology, EarlyView.Inhibition of protein SUMOylation has been shown to block tumorigenesis; however, the specific mechanisms by which SUMOylation controls the tumor‐initiating capacities remain elusive. Li et al. describe the role of Etv1 SUMOylation in cancer stem cells using mouse models of mammary gland tumorigenesis.
Veronika Yevdokimova, Yannick D. Benoit
wiley +1 more source
Cancer Management and Research, 2022 Belson Rugwizangoga,1,2,* Narcisse Niyikora,3,* Angèle Musabyimana,3,* Annie-Isabelle Izimukwiye,4 Johan Aurelius,2 Anna Martner,2 Aline Umubyeyi3 1University Teaching Hospital of Kigali, School of Medicine and Pharmacy, College of Medicine ...
Rugwizangoga B +6 more
doaj
Gefitinib induces myeloid differentiation of acute myeloid leukemia
Blood, 2005 AbstractCure rates for patients with acute myeloid leukemia (AML) remain low despite ever-increasing dose intensity of cytotoxic therapy. In an effort to identify novel approaches to AML therapy, we recently reported a new method of chemical screening based on the modulation of a gene expression signature of interest.
Jenny S. Wong +5 more
openaire +4 more sources
Molecular Oncology, EarlyView.In prostate carcinoma, lactic acid, secreted by highly glycolytic cancer‐associated fibroblasts, is imported into tumor cells through the MCT1 transporter and prevents RSL3 and erastin‐induced ferroptosis (A). Targeting of carbonic anhydrase IX/XII, the main extracellular pH regulators, in tumor and stromal cells reduces microenvironmental acidosis and
Elisa Pardella +18 more
wiley +1 more source
Molecular Oncology, EarlyView.Stemness properties, including quiescence, self‐renewal, and chemoresistance, are closely associated with leukemia relapse. Here, we demonstrate that DNA damage‐inducible transcript 4 (DDIT4) is induced in the hypoxic bone marrow niche and is essential for maintaining the stemness of AML1‐ETO9a leukemia cells.
Yishuang Li +12 more
wiley +1 more source
Molecular Oncology, EarlyView.Microglia (BV2) and IL‐4‐treated BMDMs promote astrocytoma clustering and inhibit tumor growth, not shown in other macrophage cells. In vivo, microglial co‐implantation enhances CD8+ T cell infiltration, elevates Granzyme B, lowers circulating MDSCs, and extends survival only in immune‐competent mice, but not in immune‐deficient mice.
Tzu‐Chieh Sun +5 more
wiley +1 more source